Shire Sheds Dermagraft; Exits Regenerative Medicine
This article was originally published in The Pink Sheet Daily
Executive Summary
The Irish specialty pharma has divested an underperforming unit, but not without a significant write-off. Yet, investors and analysts applaud the decision.
You may also be interested in...
Market Intel: Intense Competition, Innovation Drive Healing Trends In Wound Care
The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.
Sanofi Should Take Note: As CEO Picks, Insiders Have History On Their Side
As Sanofi looks for a replacement for Chris Viehbacher, it might want to take the recent track records of the CEOs at its competitors into consideration before making a decision.